UCLA TECHs - LifeSci/Biotech

UCLA PATENTS AND INVENTIONS AVAILABLE FOR LICENSING

Peptide for Induction of Immune Tolerance as Treatment for Systemic Lupus Erythematosus (SLE)

		By Bob Nidever in Latest Additions Published: Monday, 07 July 08 - 11:06 PM (GMT)

UCLA investigators have invented the D form of an artificial synthetic peptide to induce suppressive T cells that prevent anti-DNA production in mice. The L form of the peptide is administered by injection; however, the new D form of the peptide is designed to be administered orally.

UCLA researchers have identified the D form of a peptide called “D-pCons” for the D form of pConsensus. When the L-form of this autoantibody-based peptide is administered to a mouse model of SLE, it induces regulatory T cells to prevent autoantibody production and nephritis. In vitro, the L form also expands regulatory T cells in patients with SLE. The D form of the peptide should be resistant to degradation by acid and proteases, so oral administration is possible. The route of administration and safety should have an advantage over the injected L form of the peptide. Recent studies using the D form show intravenous expression significantly reducing α-DNA production. Additionally, studies demonstrating the efficacy of D-pCons are underway. MORE [2008-211]
<-- Back